High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting
- Resource Type
- Authors
- Philipp Diehl; Katharina Schnabel; Patrick Weik; Anne Charlet; Jennifer S. Esser; Christoph Bode; Jonathan Rilinger; Melanie Meyer; Qian Zhou; Martin Moser; Christoph B. Olivier
- Source
- Journal of thrombosis and thrombolysis. 42(4)
- Subject
- Blood Platelets
Male
medicine.medical_specialty
medicine.medical_treatment
030204 cardiovascular system & hematology
03 medical and health sciences
0302 clinical medicine
P2Y12
Risk Factors
Internal medicine
Thromboembolism
Antithrombotic
Atrial Fibrillation
Medicine
Humans
In patient
030212 general & internal medicine
Risk factor
Aged
Aged, 80 and over
Hematology
business.industry
Coronary stenting
Percutaneous coronary intervention
Atrial fibrillation
medicine.disease
Platelet Activation
Coronary Vessels
Receptors, Purinergic P2Y12
Cardiology
Drug Therapy, Combination
Female
Stents
Cardiology and Cardiovascular Medicine
business
Platelet Aggregation Inhibitors
- Language
- ISSN
- 1573-742X
High platelet reactivity (HPR) after P2Y12-inhibition in patients undergoing coronary stenting is associated with an increased risk for thromboembolic events and coronary death. So far it is not known how HPR affects the clinical outcome of different treatment strategies in patients with atrial fibrillation (AF) undergoing coronary stenting. In this single centre, observational study the antiplatelet effect of P2Y12-inhibitors in AF patients undergoing coronary stenting was investigated using impedance aggregometry. Patients received either dual antiplatelet therapy (DAPT) or triple therapy (TT). HPR was defined as the ratio of ADP-to TRAP-induced aggregation (r-ADP-agg) ≥50 %. Thromboembolic and bleeding events were assessed within the first 30 days after stenting. Out of 910 screened patients 167 patients were available for the present analysis. HPR was found in 5 of 43 (12 %) patients treated with DAPT and in 18 of 124 (15 %) patients treated with TT. In patients receiving TT, HPR was not a risk factor for thromboembolic events compared to patients with adequate response to P2Y12-inhibitors (6 vs. 8 %, p = 0.712). There was a trend for less bleeding events in patients with HPR compared to r-ADP-agg